0500 Evaluation of the Human Abuse Potential of Single Oral Doses of V117957, a Novel, Highly Potent and Selective Partial Agonist for Nociceptin/Orphanin-FQ Peptide (NOP) Receptors
Sign Up to like & getrecommendations! Published in 2020 at "Sleep"
DOI: 10.1093/sleep/zsaa056.497
Abstract: The satisfactory safety/tolerability profile of V117957, an investigational NOP receptor partial agonist, has been previously established in ~200 healthy subjects with maximum doses at 30mg following a single oral administration and 10mg once daily for… read more here.
Keywords: abuse potential; v117957 1mg; placebo; partial agonist ... See more keywords